Effect of Yupingfeng granules on HA and Foxp3^+ Treg expression in patients with nasopharyngeal carcinoma

Objective: To investigate the effect of Yupingfeng on hyaluronic acid(HA) and Foxp3+ Treg in patients with nasopharyngeal carcinoma. Methods: A total of 58 cases of nasopharyngeal carcinoma were divided into two groups, 30 cases in the treatment group, 28 cases in the control group. Patients in two groups were treated with synchronous radiotherapy and chemotherapy treatment, the treatment group was treated with the Yupingfeng granules through oral administration, 10 g/time, tid for 2 courses. The serum Foxp3+ Treg markers of each group were detected by flow cytometry assay before treatment and after treatment, and the level of HA in serum was detected by radio immunoassay. Results: After radiotherapy and chemotherapy, the contents of Foxp3+ Treg and HA were significantly decreased in two groups(P<0.05), and the decrease of treatment group was more significantly(P<0.01). Correlation analysis showed positive correlation between Foxp3+ Treg and HA(P<0.05). After treatment, the incidence of side effects in two groups was significantly decreased. And there was significant difference between two groups(P<0.05). Conclusions: Combined chemotherapy and radiotherapy with Yupingfeng treatment can decrease the levles of Foxp3+ Treg and HA in nasopharyngeal carcinoma patients. Yupingfeng can also effectively reduce the side effect due to radiation and chemotherapy.

Effects of Yupingfeng Polysaccharides on the Spleen Tissue Structure of Acute and Chronic Immunocompromised Mice

[Objectives] To study the protective and recovery effects of Yupingfeng polysaccharides( YPF-P) on spleen tissue structure of acute and chronic immunocompromised mice. [Methods]First,90 mice in the protective group were injected with cyclophosphamide to replicate the chronic immunosuppressive model,and observe the protective effects of different doses of YPF-P on the spleen; 120 mice in the recovery group were injected with cyclophosphamide continuously to replicate the acute immune injury model,to observe the effects of YPF-P on spleen recovery. Besides,YPF-P positive control group was established to observe its effects on the spleen structure and function of normal mice. Testing indicators include spleen morphology and tissue structure,body mass,and spleen index. [Results]In the protective group and the recovery group,the spleen volume of the mice with different YPF-P doses increased significantly,and lymphocytes proliferated,showing obvious structural compensation and repair,and showing a dose-effect relationship. In the positive control group,the spleen function of the normal mice was significantly enhanced,and the spleen lymphoid tissue showed significant orderly proliferation. [Conclusions]Yupingfeng polysaccharides can effectively protect the function and structure of spleen,improve acute and chronic immune damage induced by cyclophosphamide,greatly promote the recovery of spleen structure and function after immune injury,and also can significant enhance the spleen structure and function of normal mice.

Effect of Yupingfeng Polysaccharide on Serum IL-2 and IFN-γ Levels in Immunosuppressive Mice

[Objective] The paper was to discuss regulation and protection effect of Yupingfeng polysaccharide （YPF-P） on immunosuppressive mice. [Method] Taking immunosuppressive mice induced by 80 mg/kg cyclophosphamide as test animal model, effects of different doses （100,200 and 400 mg/kg） of YPF-P on spleen index, serum IL-2 and IFN-γ levels of mice were studied. [ Result] High dose of YPF-P （400 mg/kg） could improve the spleen index of immunosuppressive mice （P 〈0.05）. YPF-P could enhance serum IL-2 and IFN-γ levels of immunosuppressive mice, and the effects in middle-dose group and low-dose group were better. YPF-P could significantly increase serum IL-2 level of normal mice （ P 〈 0.01 ）, but it had no significant effect on serum IFN-γ level of normal mice. [ Conclusion] The research provides an experimental basis for clinical application of YPF-P.

Study on the mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking method

Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,query the chemical composition and action target of Yupingfeng powder,query the disease database of Genecards,OMIM,DisGeNET,Drugbank,etc.,use"non-small cell lung cancer"as the keyword to search the disease-related target,select the intersection target with Yupingfeng powder as the research target,and use Cytoscape 3.7.2 software to construct the active component-target network map.The protein-protein interaction network map was constructed by using STRING database,and the treatment core targets were further screened by topological parameters,and GO analysis and KEGG signal pathway enrichment analysis were carried out.Finally,molecular docking was verified.Results:37 active components of Yupingfeng Powder were screened,including 146 common targets and 44 core targets.GO analysis and KEGG analysis show that the core target participates in many biological processes such as angiogenesis and cell proliferation,and acts on a variety of signal pathways such as AGE-RAGE,IL-17,TNF,MAPK and so on.Molecular docking shows that the core compound has good docking activity with the target.Conclusion:Network pharmacological analysis shows that Yupingfeng powder in the treatment of non-small cell lung cancer involves multi-target and multi-pathway mechanism,and the drug and target have good docking activity,which can provide theoretical basis for follow-up experimental research.

Systematic review and meta-analysis of additional Yupingfeng powder combined with western medicine treatment at stable period of chronic obstructive pulmonary disease

Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.

Research Progress of Yupingfeng Powder in Clinical Application

Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summarized and analyzed the diseases he treated,providing ideas and methods for clinical users.

Impact of Yupingfengsan Oral Liquid on the Expression of IL-4, IFN-<i>γ</i>and NF-<i>κ</i>B of Allergic Rhinitis Mice

To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-γ in AR mice’s serum and expression level of nuclear factor—κB (NF-κB) protein and gene in nasal mucosa. Method: Forty BALB/c mice were randomly divided into the normal group, model group, Yupingfengsan Oral Liquid group (6 g/kg) and Loratadine group, with 10 mice per group. AR mice model was established by OVA, and IL-4 and IFN-γ contents can be measured with ELISA. The morphological changes of nasal mucosa were observed by hematoxylin eosin (HE) staining and NF-κB expression in the nasal mucosa of mice was tested with Real-Time PCR and Western blot. Results: Compared with the model group, the nasal symptoms in the Yupingfengsan Oral Liquid group and Loratadine group were obviously relieved. HE staining showed that there was a little inflammatory cell infiltration in the nasal mucosa of Yupingfengsan Oral Liquid group and Loratadine group and it was significantly reduced when compared with the model group. IL-4 level in the serum and expression of NF-κB protein and gene in the nasal mucosa was consistent and it was decreased when compared with the model group (P < 0.01), but the IFN-γ level in the serum was increased (P < 0.01). Conclusion: Yupingfengsan Oral Liquid can improve the clinical symptoms and histopathological manifestations of AR mice sensitized by OVA, inhibit the NF-κB expression, balance the percentage of Th1/Th2 cells, increase the IFN-γ level in the serum and decrease the IL-4 level.

Yupingfeng Powder regulates immunity in patients with stable chronic obstructive pulmonary disease: a meta-analysis

Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to search databases such as China National Knowledge Infrastructure(CNKI),VIP Database,China Biology Medicine disc(CBMdisc),Wanfang Database,PubMed,Cochrane Library,etc.Search all randomized controlled trials(RCTs)of YPFP in the treatment of stable chronic obstructive pulmonary disease,with CD4,CD8,CD4/CD8,IgE,IgA,IgM,and IgG as the outcome indicators.Two reviewers independently conducted literature search,conducted literature quality evaluation with the risk bias assessment tool recommended by Cochrane Handbook,and conducted data extraction,discussed and resolved disputes,and used RevMan 5.3 software for Meta-analysis.Results:A total of 11 randomized controlled trials with 1,058 patients were included.According to the Meta-analysis,the results of the effectiveness analysis showed that after oral administration of YPFP in the stable phase of chronic obstructive pulmonary disease,the test group CD3,CD4,CD8,CD4/CD8,IgA,IgE,IgM,IgG8 were better than the control group(P<0.05).Conclusion:Oral administration of YPFP in the stable period of chronic obstructive pulmonary disease can effectively regulate the immunity.However,the number of studies included in this study is small and the heterogeneity is large,and it is still necessary to design high-quality clinical trials for in-depth research.

Efficacy of Sodium Cromoglicate Eye Drops Combined with Yupingfeng Granules in the Treatment of Allergic Conjunctivitis

Purpose:To observe the clinical efficacy of sodium cromoglicate eye drops combined with Yupingfeng granules in the treatment of allergic conjunctivitis.Methods:.A total of 118 patients with allergic conjunctivitis were randomly divided into a combined sodium cromoglicate and Yupingfeng Granule (treatment)group(n=74) and a sodium cromoglicate (control) group (n=44).Clinical efficacy of the two treatments was evaluated by observing the changes in patients'symptoms and physical signs before and after their respective treatments.Results:.Following treatment,.the symptoms and physical signs related to allergic conjunctivitis were significantly alleviated in all 118 cases.The total efficacy of the combined sodium cromoglicate and Yupingfeng granule treatment was91.9%,.which was significantly higher than the value of 75.0%obtained with sodium cromoglicate alone(P<0.05).Conclusion:.Combined therapy of sodium cromoglicate eye drops and Yupingfeng granules had a high efficacy and no significant adverse reactions..Therefore,.this treatment deserves to be considered for wide application in clinical settings.

玉屏风煎剂对德化黑鸡生长性能、免疫调节、血清生化指标的影响

【目的】探讨玉屏风煎剂对德化黑鸡生长性能、免疫调节、血清生化指标的影响,并对其安全性进行观察。【方法】黄芪、白术、防风按质量比2:2:1混合煎制,浓缩成含生药1 g·mL^(-1)的玉屏风煎剂。将30日龄体重相近的德化黑鸡160头随机分为低剂量组(1.25 mL·头^(-1)·天^(-1))、中剂量组(1.875 mL·头^(-1)·天^(-1))、高剂量组(2.5mL·头^(-1)·天^(-1))和空白对照组(0 mL·头^(-1)·天^(-1)),每组4个重复,每个重复10头,煎制玉屏风饮水给药,饲喂试验为期25 d;试验第25 d采血及十二指肠,检测生长性能、十二指肠形态结构、免疫功能、抗氧化能力、血清生化等相关指标。【结果】与对照组相比,1)中、高剂量组日增重分别提高16.77%(P<0.05)、27.58%(P<0.01),3个剂量组饲料转化率分别提高8.30%、14.61%、21.92%;2)3个剂量组血清IL-2含量,中、高剂量组十二指肠黏膜SIgA水平显著提高(P<0.05或P<0.01);3个剂量组血清IFN-γ、TNF-α含量显著降低(P<0.05或P<0.01)。3)3个剂量组MDA浓度极显著降低(P<0.01),GSH-Px、SOD活性极显著升高(P<0.01),高剂量组T-AOC、CAT活性显著升高(P<0.05或P<0.01)。4)中、高剂量组隐窝深度显著降低(P<0.05),绒隐比显著增加(P<0.05或P<0.01);5)3个剂量组总胆红素浓度、甘油三酯浓度、总胆固醇浓度、谷草转氨酶活性、谷丙转氨酶活性、碱性磷酸酶活性、肌酐浓度、肌酸激酶活性差异均不显著(P>0.05)。【结论】玉屏风煎剂可以提高德化黑鸡的生长性能,改善肠道形态结构,强化抗氧化能力,增强免疫功能,具有抗炎、维持免疫平稳态的作用,使用安全,最适剂量为2.5 mL·头^(-1)·天^(-1)。

华西广医1号急性毒性、鼻黏膜刺激性和增强免疫功能的研究

为初步了解拟开发医院雾化制剂华西广医1号的安全性和有效性,通过小鼠急性毒性试验、大鼠鼻黏膜刺激性试验和增强免疫功能的药效学试验方法研究了华西广医1号安全性和药效。结果表明:以0.34 g/mL药液24 h内雾化给药,对小鼠无明显急性毒性;对大鼠经鼻腔给药无明显刺激性;以0.068 g/mL雾化给药,有升高幼龄小鼠的胸腺指数的作用趋势;可升高环磷酰胺致免疫功能低下小鼠的巨噬细胞碳粒廓清指数K、校正指数α和外周血白细胞数目(white blood cell,WBC),红细胞数目(red blood cell,RBC)和血红蛋白浓度(hemoglobin,HGB)水平,并可升高溶血素值。可见,华西广医1号雾化给药小鼠的最大给药量为34 g/kg,无明显鼻黏膜刺激性,0.068 g/mL雾化给药有增强免疫功能,可用于预防上呼吸道感染。

玉屏风多糖复合益生菌对大口黑鲈响应迟缓爱德华氏菌脂多糖的免疫调节作用

为探究玉屏风多糖复合益生菌对大口黑鲈(Micropterus salmoides)响应迟缓爱德华氏菌(Edwardsiellatarda)脂多糖(LPS)的免疫调节作用,选取450尾健康大口黑鲈(11±2)g,随机分为对照组、复合益生菌组(CPB)、玉屏风多糖组(YPF)、未发酵玉屏风多糖复合益生菌组(UYP)和发酵玉屏风多糖复合益生菌组(FYP)5组,饲喂28 d后注射迟缓爱德华氏菌LPS,在注射后0、8、24、48 h采样,测定免疫器官生长指数、血清生化指标、组织抗氧化指标和肝脏免疫相关基因表达。结果显示:饲喂28 d后,FYP组头肾指数显著高于对照组和YPF组。在LPS免疫刺激0 h时,实验组血清总抗氧化能力均显著高于对照组。免疫刺激8 h时UYP组和FYP组血清谷草转氨酶和谷丙转氨酶活性显著高于对照组,肝脏白细胞介素-1和肿瘤坏死因子-α浓度显著高于对照组,肝脏核因子-κB抑制物激酶、白细胞介素-1β、白细胞介素-8相对表达量较对照组均显著下调。与其他实验组相比,FYP组在免疫刺激后8 h时肠组织和肝组织超氧化物歧化酶活性显著高于其他组,48 h时血清免疫球蛋白M浓度显著高于其他组。综上,本研究表明玉屏风多糖与复合益生菌均能提高大口黑鲈的免疫能力,发酵玉屏风多糖复合益生菌效果更佳。

中成药治疗慢性阻塞性肺疾病稳定期的网状Meta分析

目的:采用网状Meta分析评价口服中成药治疗慢性阻塞性肺疾病(COPD)稳定期的有效性及安全性。方法:计算机检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBM)、PubMed、Embase、Web of Science、Cochrane library数据库中不同中成药治疗COPD稳定期的临床随机对照试验(RCT),检索时限为建库至2022年05月11日。采用R 4.1.1、Stata 16.0、Review manager 5.3软件进行数据分析。结果:共纳入70项RCT,包括6652例患者,涉及5种中成药。依据累计概率值排序,网状Meta分析结果显示,改善COPD自我评估测试(CAT)问卷评分方面,百令胶囊+常规治疗(>常规治疗;改善第一秒用力呼气容积占预计值百分比(FEV_(1)%)方面,百令胶囊+常规治疗>金水宝胶囊+常规治疗>补肺活血胶囊+常规治疗>玉屏风颗粒+常规治疗>常规治疗);改善六分钟步行距离(6MWD)方面,金水宝胶囊+常规治疗>补肺活血胶囊+常规治疗>百令胶囊+常规治疗>常规治疗;降低二氧化碳分压方面(PaCO_(2)),补肺活血胶囊+常规治疗>金水宝胶囊+常规治疗>百令胶囊+常规治疗>常规治疗;降低年急性发作次数方面,百令胶囊+常规治疗>常规治疗。5种中成药均未产生严重不良反应。结论:5种中成药治疗稳定期COPD均能提高临床综合疗效,但各有侧重,其中百令胶囊组综合疗效较好。

玉屏风散加减联合西药治疗促进轻型新冠病毒感染孕妇核酸转阴的疗效观察

[目的]探讨玉屏风散加减联合西药治疗轻型新冠病毒感染孕妇的临床疗效。[方法]以上海市公共卫生临床中心2022年4月至6月收治的轻型新冠病毒感染孕妇作为研究对象,随机分成治疗组(48例)及对照组(52例)。对照组给予退热、止咳对症及维生素C等西药治疗,治疗组在对照组基础上给予玉屏风散加减治疗。对比两组患者治疗前后的各症状积分、不良妊娠结局发生率、总有效率和淋巴细胞、C反应蛋白、白细胞介素-2受体、白细胞介素-6等实验室指标变化,并观察两组患者病毒核酸转阴和疾病转归情况。[结果]与对照组比较,治疗组症状总积分显著下降(P<0.001),总有效率显著升高(P<0.01),炎症指标C反应蛋白、白细胞介素-6水平较前显著下降(P<0.001,P<0.01),而淋巴细胞计数较前显著升高(P<0.001),不良妊娠结局发生率两组间差异无统计学意义(P>0.05)。[结论]玉屏风散加减联合西药治疗可显著改善轻型新冠病毒感染孕妇的临床症状,缩短核酸转阴时间,且不会增加不良妊娠结局,具有一定的临床价值,值得临床推广应用。

静脉注射热毒宁联合玉屏风颗粒对邪毒犯心型儿童病毒性心肌炎的疗效

目的探讨静脉注射热毒宁注射液联合口服玉屏风颗粒对邪毒犯心型病毒性心肌炎(VMC)患儿的临床疗效及对炎症因子、心功能指标的影响。方法选择邪毒犯心型VMC患者147例,随机分为对照组50例、热毒宁组48例及热毒宁联合玉屏风颗粒组(联合组)49例,比较3组患儿的临床疗效、炎症因子变化及心功能指标。结果治疗1周后热毒宁组及联合组的治疗总有效率均优于对照组,热毒宁组及联合组的TNF、IL-6及IFN-γ等指标均明显低于对照组(P<0.01),联合组的IFN-γ低于热毒宁组。热毒宁组及联合组的CK-MB、BNP等指标均明显低于对照组,联合组的cTNI低于对照组及热毒宁组(P<0.01)。治疗两周后热毒宁组及联合组的治疗总有效率均明显优于对照组,联合组有效率优于热度宁组(P<0.01);热毒宁组及联合组的TNF、IL-6及IFN-γ等指标均明显低于对照组,联合组的TNF、IFN-γ等指标均明显低于热毒宁组(P<0.01)。热毒宁组及联合组的CK-MB、cTNI及BNP等指标均明显低于对照组,联合组的CK-MB、cTNI等指标均明显低于热毒宁组(P<0.01)。结论静脉注射热毒宁注射液佐以口服玉屏风颗粒能够有效提高邪毒犯心型儿童VMC的治疗有效率,改善其预后,这可能与其能够有效降低相关的炎症因子水平,降低心肌损伤标志物水平,修复心肌细胞有关。

玉屏风颗粒对过敏性鼻炎患者通气功能及炎性反应的影响

目的 探究玉屏风颗粒对过敏性鼻炎(AR)患者通气功能及炎性反应的影响。方法 80例AR患者,随机分成对照组和观察组,每组40例。对照组使用常规治疗,观察组在对照组基础上加用玉屏风颗粒联合治疗。比较两组通气功能[最大呼气流速(PEF)、PEF昼夜变异率]、炎性反应指标[白细胞介素(IL)-6、IL-17、IL-23、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]、免疫功能[免疫球蛋白(Ig)A、IgG、IgE]、症状评分、治疗效果及临床症状改善时间。结果 治疗后,两组PEF均高于治疗前, PEF昼夜变异率均低于治疗前,且观察组PEF(73.30±7.91)L/min高于对照组的(62.97±6.43)L/min, PEF昼夜变异率(13.34±2.45)%低于对照组的(17.74±3.65)%(P<0.05)。治疗后,观察组IL-6(131.52±11.17)ng/L、IL-17(3.13±0.27)ng/L、IL-23(151.56±18.25)ng/L、CRP(4.28±0.22)mg/L、TNF-α(7.44±1.18)ng/L均低于对照组的(159.65±18.15)ng/L、(4.44±0.51)ng/L、(215.31±31.30)ng/L、(6.28±0.94)mg/L、(12.50±2.20)ng/L(P<0.05)。治疗后,观察组IgA(1.48±0.18)g/L、IgG(12.65±1.70)g/L高于对照组的(1.03±0.22)、(9.83±1.14)g/L, IgE(418.41±48.36)IU/ml低于对照组的(625.28±76.29)IU/ml(P<0.05)。治疗后,观察组鼻涕、鼻塞、鼻痒、喷嚏评分均低于对照组(P<0.05)。观察组治疗总有效率高于对照组(P<0.05)。观察组鼻塞改善时间、鼻痒改善时间、喷嚏改善时间、流涕改善时间均短于对照组(P<0.05)。结论 为AR患者应用玉屏风颗粒治疗效果显著,有利于促进患者病情康复。

玉屏风颗粒联合卡介菌多糖核酸治疗慢性荨麻疹的效果分析

目的:探讨玉屏风颗粒联合卡介菌多糖核酸治疗慢性荨麻疹的效果。方法:选取2021年7月—2023年7月滨州市中心医院收治的慢性荨麻疹患者96例作为研究对象,随机分为试验组和对照组,各48例。对照组采用卡介菌多糖核酸治疗,试验组在对照组基础上采用玉屏风颗粒治疗。比较两组治疗效果。结果:治疗后,试验组瘙痒程度、风团数目、每日风团发作次数、风团最大直径、匹兹堡睡眠质量指数、皮肤病生活质量指数评分,白细胞介素-4、白细胞介素-10、CD8^(+)水平,复发率均低于对照组,白细胞介素-2、CD3^(+)、CD4^(+)水平均高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:玉屏风颗粒联合卡介菌多糖核酸治疗慢性荨麻疹的效果良好,能够改善患者临床症状、睡眠质量与生活质量,减轻炎性反应,提高免疫功能,减少复发,且安全性较高。

基于NF-κB信号通路的玉屏风散加味含药血清对RLE-6TN细胞炎症反应的影响

目的观察玉屏风散加味含药血清对大鼠肺上皮Ⅱ型细胞RLE-6TN炎症反应的影响,基于核因子(NF)-κB信号通路探讨其作用机制。方法采用脂多糖诱导RLE-6TN细胞炎症反应,将细胞分为对照组、模型组、地塞米松血清组和5%、10%、20%中药血清组,分别以不同血清干预细胞24 h。试剂盒检测细胞上清液乳酸脱氢酶(LDH)含量,荧光染色检测细胞活性氧(ROS)含量,Hoechst/PI双染观察细胞凋亡情况,ELISA检测细胞上清液肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-6、IL-1β含量,RT-qPCR检测细胞Toll样受体4(TLR4)、髓样分化因子88(MyD88)、NF-κB抑制蛋白α(IκBα)mRNA表达,Western blot检测细胞TLR4、MyD88、NF-κBp65、IκBα蛋白表达。结果与对照组比较,模型组RLE-6TN细胞上清液LDH、TNF-α、IL-6、IL-1β及细胞ROS含量显著升高(P<0.01),细胞凋亡率显著升高(P<0.01),TLR4、MyD88 mRNA和蛋白表达显著升高(P<0.01),IκBαmRNA表达显著降低(P<0.01),p-NF-κBp65/NF-κBp65、p-IκBα/IκBα比值显著升高(P<0.01);与模型组比较,20%中药血清组和地塞米松血清组细胞RLE-6TN细胞上清液LDH、TNF-α、IL-6、IL-1β及细胞ROS含量显著降低(P<0.01),细胞凋亡率显著降低(P<0.01),TLR4、MyD88 mRNA和蛋白表达显著降低(P<0.05,P<0.01),IκBαmRNA表达显著升高(P<0.01),p-NF-κBp65/NF-κBp65、p-IκBα/IκBα比值显著降低(P<0.05,P<0.01)。结论玉屏风散加味含药血清可减轻RLE-6TN细胞炎症反应,其机制可能与调控NF-κB信号通路有关。

加味玉屏风散治疗气虚毒瘀型晚期肝癌的临床研究

目的观察加味玉屏风散治疗气虚毒瘀型晚期肝癌的临床疗效及对患者血清胸腺基质淋巴细胞生成素(TSLP)水平的影响。方法采用随机双盲法将120例气虚毒瘀型晚期肝癌患者分为加味玉屏风散组、玉屏风散组和安慰剂组各40例,3组患者均给予放疗、化疗、介入或靶向治疗等常规治疗,加味玉屏风散组加服加味玉屏风散颗粒,玉屏风散组加服玉屏风散颗粒,安慰剂组加服安慰剂,疗程均为2个月。治疗前后观察3组患者Karnofsky功能状态评分(KPS评分)、中医证候积分、瘤体大小及血清TSLP水平变化情况,并将肿瘤大小变化与TSLP变化进行相关性分析。结果治疗后,玉屏风散组及加味玉屏风散KPS评分均显著提高(P<0.05,P<0.01),中医证候总积分显著降低(P<0.01),同时明显延缓肿瘤的生长(P<0.05,P<0.01),显著降低血清中TSLP水平(P<0.05,P<0.01)。此外,肿瘤大小变化与TSLP变化呈轻度正相关(P<0.05)。在改善瘤体大小方面,加味玉屏风散组疗效优于玉屏风散组(P<0.05)。治疗期间,3组患者均未见明显不良反应。结论加味玉屏风散联合常规治疗可显著延缓气虚毒瘀型晚期肝癌患者的肿瘤生长,改善患者中医症状同时显著提高患者生存质量,其疗效机制可能为通过降低患者血清TSLP表达,改善机体免疫状态有关。

玉屏风散通过ZBP1介导的巨噬细胞泛凋亡抑制哮喘气道炎症的机制研究

目的:观察玉屏风散对ZBP1介导的肺泡巨噬细胞泛凋亡的影响,从而阐明其抑制哮喘气道炎症的分子机制。方法:采用脂多糖诱导肺泡巨噬细胞(MH‑S)构建哮喘细胞模型,并给予不同浓度玉屏风散含药血清进行干预,分别采用CCK8法检测NH‑S细胞活性,ELISA法检测LDH、IL‑1β和IL‑18的含量,流式细胞术检测细胞死亡情况,Western blot法检测泛凋亡相关蛋白和ZBP1蛋白的表达,RT‑qPCR法检测ZBP1基因的表达。结果:与空白组相比,模型组肺泡巨噬细胞LDH释放、IL‑1β与IL‑18的含量和死亡细胞比例显著增加,细胞焦亡蛋白Cleaved caspase‑1与GSDMD‑NT、坏死性凋亡蛋白p‑RIPK3与p‑MLKL、凋亡蛋白Cleaved caspase‑3的表达显著上调,差异均具有统计学意义(P<0.01)。与模型组相比,玉屏风散组肺泡巨噬细胞LDH释放、IL‑1β与IL‑18的含量和死亡细胞比例显著降低,细胞焦亡蛋白Cleaved caspase‑1与GSDMD‑NT、坏死性凋亡蛋白p‑RIPK3与p‑MLKL、凋亡蛋白Cleaved caspase‑3的表达显著下调,差异均具有统计学意义(P<0.01)。此外,与模型组相比,玉屏风散组肺泡巨噬细胞中ZBP1蛋白和ZBP1mRNA的表达显著降低,差异均具有统计学意义(P<0.01)。结论:玉屏风散通过抑制巨噬细胞中ZBP1的表达,从而抑制细胞泛凋亡水平改善气道炎症。